136 related articles for article (PubMed ID: 15961781)
21. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
Kumpulainen EJ; Hirvikoski PP; Johansson RT
Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
[TBL] [Abstract][Full Text] [Related]
22. Case 6-1985: progressive pneumonitis after chemotherapy for breast cancer.
N Engl J Med; 1985 Jul; 313(1):49-50. PubMed ID: 3839046
[No Abstract] [Full Text] [Related]
23. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
24. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
25. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer.
Cathomas R; Pelosi E; Smart J; Murray N; Simmonds P
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):292-3. PubMed ID: 15997927
[No Abstract] [Full Text] [Related]
26. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
[TBL] [Abstract][Full Text] [Related]
27. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy.
Andersen KE; Lindskov R
Photodermatol; 1984 Jun; 1(3):129-32. PubMed ID: 6527953
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients.
Kopjar N; Milas I; Garaj-Vrhovac V; Gamulin M
Hum Exp Toxicol; 2007 May; 26(5):391-9. PubMed ID: 17623763
[TBL] [Abstract][Full Text] [Related]
29. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
30. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
31. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.
Bonadonna G; Valagussa P; Veronesi U
J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404
[No Abstract] [Full Text] [Related]
32. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline-based adjuvant chemotherapy in breast cancer.
Montemurro F; Aglietta M
Lancet; 2010 May; 375(9729):1871; author reply 1871-2. PubMed ID: 20511012
[No Abstract] [Full Text] [Related]
34. Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer.
Sica S; Salutari P; Ciarli M; Piccirillo N; Laurenti L; Menichella G; Leone G
Leukemia; 1997 Nov; 11(11):1990-2. PubMed ID: 9369440
[No Abstract] [Full Text] [Related]
35. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy)].
Nagashima Y; Sanpei N; Yamamoto S; Yoshino S; Tangoku A; Oka M
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1550-2. PubMed ID: 16315865
[TBL] [Abstract][Full Text] [Related]
37. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
Colleoni M; Price KN; Castiglione-Gertsch M; Gelber RD; Coates AS; Goldhirsch A
Lancet; 1999 Jul; 354(9173):130-1. PubMed ID: 10408495
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related leukemia cutis after adjuvant chemotherapy in a breast cancer patient.
Lee HY; Ng HJ; Wong PC; Pang SM
Acta Derm Venereol; 2010 Nov; 90(6):649-50. PubMed ID: 21057758
[No Abstract] [Full Text] [Related]
39. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
40. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
